Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease.
Twenty-seven patients with peripheral atherosclerotic disease were r and omized into two therapy regimens consisting of indobufen ( Indo ) ( 400 mg/day ) and dipyridamole ( Dip ) ( 225 mg/day ) plus acetylsalicylic acid ( ASA ) ( 1 g/day ) , respectively . Maximal walking distance ( MWD ) and ankle-arm systolic pressure ratios were measured before and after three and six months of therapy ; bleeding time , beta-thromboglobulin ( beta-TG ) , platelet factor 4 ( PF4 ) and serum thromboxane B2 ( TXB2 ) were also assessed . The two treatment groups showed a significant and progressive increase in pain-free walking distance at both three and six months of therapy , but patients taking indobufen showed a greater improvement . On the contrary , the pressure doppler ratio at rest was statistically improved only in the ASA plus Dip group . Basal beta-TG and PF4 levels were normal and no changes occurred during the study in either group , while in all patients bleeding times showed a significant increase above basal values and serum TBX2 decreased
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .